Clinical trial
Expanded Access for KHK2455
Name
Expanded Access for KHK2455
Description
This is an expanded access program for eligible participants. This program is designed to provide access to KHK2455 in combination with Mogamulizumab prior to the approval by the local regulatory agency. A medical doctor must decide whether the potential benefit outweighs the risk of receiving this investigational therapy based on the individual patients medical history and eligibility criteria.
Trial arms
Treatment
KHK2455
Other names:
Mogamulizumab
Size
-1
Eligibility criteria
Inclusion Criteria:
-
Exclusion Criteria:
-
Protocol
{'studyType': 'EXPANDED_ACCESS', 'nPtrsToThisExpAccNctId': 1, 'expandedAccessTypes': {'individual': True}}
Updated at
2024-04-25
1 organization
1 product
1 indication
Organization
Kyowa KirinProduct
KHK2455Indication
Glioblastoma Multiforme